NEW YORK, May 30 – Incyte Genomics and Iconix Pharmaceuticals announced on Wednesday a collaboration to develop and commercialize the next-generation of Iconix’s ChemExpress chemogenomic platform.
Incyte will exclusively market and sell ChemExpress, according to the companies. Iconix will integrate Incyte’s LifeExpress Lead databases into ChemExpress under an exclusive license from Incyte, the companies announced. Under the terms of the agreement, Incyte will make an equity investment in Iconix.
Financial terms of the collaboration and the size of the equity stake Incyte will receive were not disclosed.
The agreement will also grant Iconix a non-exclusive license to access Incyte’s LifeSeq and ZooSeq databases. Iconix will maintain exclusive rights to enter into proprietary chemogenomics collaborations with other partners, according to the companies.
“ChemExpress, incorporated with our LifeExpress Lead product, will provide drug designers a powerful information and analytical system that should accelerate target prioritization, drug candidate optimization, and predictive toxicology,” Incyte CEO Roy Whitfield said in a statement.
ChemExpress is a platform that connects genomic and biological activity data with drug molecule, pharmacology, and toxicology information. Mountain View-based Iconix also has a collaboration with Motorola using its BioChip expression array technology in the development of ChemExpress.